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ABSTRACT
Objective To estimate average annual expenditures 
per person, total economic burden and distress health 
financing associated with the treatment of five cardio- 
metabolic diseases (CMDs—hypertension, diabetes, heart 
disease (angina, myocardial infarction and heart failure), 
stroke and chronic kidney disease) in three metropolitan 
cities in South Asia.
Design Cross- sectional surveys.
Setting We analysed community- based baseline data 
from the Centre for cArdio- metabolic Risk Reduction 
in South Asia (CARRS) Study collected in 2010–2011 
representing Chennai and New Delhi (India), and Karachi 
(Pakistan).
Participants We used data from non- pregnant adults 
(≥20 years) from the aforementioned cities that responded 
to a cost- of- illness questionnaire. We estimated health 
utilisation and expenditures among those reporting taking 
treatment(s) for the aforementioned CMDs in the last 
1 year. We converted all costs to International Dollars 
(Int$ 2011) and inflated to 2018 values. The annual costs 
per person were stratified by city, sociodemographic 
characteristics, contributor of costs and financing 
methods. The total economic burden of CMDs for each 
city was projected using age- standardised prevalence and 
per- person costs of diseases reported in CARRS, applying 
these to population data from the most recent census. We 
also calculated distress financing (DF) as having to borrow 
or sell assets to pay for CMD treatment and identified 
sociodemographic groups at most risk of DF using multiple 
regression.
Results Of 16 287 CARRS participants, 2883 (17.7%) 
reported receiving treatment for CMDs. The total annual 
expenditures reported per patient for CMDs ranged 
from Int$358 to Int$2425. Medications constituted 46% 
of total direct expenditures and out- of- pocket (OOP) 
expenditures accounted for nearly 80% of financing these 
health expenditures. Total economic burdens of CMDs 
were Int$0.42 billion, Int$3.4 billion and Int$1.4 billion 
in Chennai, New Delhi and Karachi, respectively. Overall, 
36.1% experienced DF, and women (OR=4.4), unemployed 
(OR=10.7) and uninsured (OR=8.1) adults experienced 
higher odds of DF.
Conclusion CMDs are associated with large economic 
burdens in South Asia. Due to most payments coming from 
OOP expenditures and limited insurance, the odds of DF 
are high.
BACKGROUND
Non- communicable disease (NCD) burdens 
are increasing worldwide, especially in low/
middle- income countries (LMICs). Cardio-
vascular diseases (CVD) and diabetes mellitus 
(DM) account for nearly 50% of NCD deaths.1 
Due to economic growth and development 
in the past two decades in South Asian coun-
tries, the burden of NCDs is increasing at 
nearly twice the rate in comparison to the rest 
of the world.2 For instance, between 1990 and 
2010, disability- adjusted life years from isch-
aemic heart disease and DM were estimated 
to have increased by 73% and 104% in South 
Asia, respectively, compared with 30% and 
70% in other parts of the world.3
Growing NCDs is a challenge for the health 
systems in South Asia that still contend with 
infectious diseases and hence face a ‘double 
burden’ of disease.4 Health systems in this 
region are not yet equipped and engineered 
to conduct early diagnosis and management 
of chronic diseases like high blood pressure, 
glucose or cholesterol. This requires robust 
primary care facilities with specific screening 
Strengths and limitations of this study
 ► First large community- based study from South Asia 
with primary data collected for cost- of- illness esti-
mation for cardio- metabolic diseases.
 ► Calculation of economic burdens for entire cities 
using prevalence and economic survey data from 
the same population which is an ideal approach to 
calculate cost of illness and loss of productivity for 
a city.
 ► First estimates of distress health financing from a 
community- based study.
 ► The health service utilisation and expenditure data 
were self- reported and are subject to reporting 
biases.
 ► Utilisation and cost of treatments were collected for 
the previous year, therefore it is subjected to recall 
bias.
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programmes and access to health education, laboratory 
facilities, and a consistent and reliable availability of 
essential medicines.4–6
Due to lack of adequate publicly funded health facili-
ties and limited health insurance coverage, most health 
expenditures are out- of- pocket (OOP) causing substan-
tial economic impacts for individuals, households and 
communities.7–11 In this context, a comprehensive evalua-
tion of the economic burden of cardio- metabolic diseases 
(CMDs) is valuable so that the financial burden of these 
diseases is adequately addressed in the universal health 
coverage reforms in these countries.12 Few published 
reports had evaluated the economic burden of CMDs.7 10 
However, existing studies have suffered from method-
ological inconsistencies, small sample sizes and limited 
availability of highly precise disease prevalence estimates. 
To address gaps in understanding of average per- person 
annual spending on CMDs and their sources of financing, 
we analysed costs of care for five CMDs namely: hyper-
tension (HTN, DM, heart disease (HD), stroke (ST) and 
chronic kidney diseases (CKD) from a large community- 
based study in India and Pakistan.
METHODS
Data collection
We used data from the baseline survey of the Centre for 
cArdiometabolic Risk Reduction in South Asia (CARRS). 
The details of the CARRS Study are published else-
where.13 14 In short, CARRS recruited 16 287 adults aged 
≥20 years using multistage cluster random sampling 
from urban cities of Chennai and New Delhi (India) 
and Karachi (Pakistan) over 2010–2011. Trained inter-
viewers collected data through household interviews in 
local languages using standardised questionnaires and 
obtained anthropometric and blood pressure measure-
ments. Fasting blood and urine samples were collected 
either at home (Karachi) or at local camps (New Delhi 
and Chennai). The cost data questions were based on 
the Initiative for Cardiovascular Health Research in the 
developing countries macroeconomic study.15
We piloted the questionnaires before the survey and 
interviewer debriefing methods were used to assess any 
difficulty or variation in understanding of the items in 
the questions; the wording of the questionnaires was then 
modified accordingly. Participants were asked if they 
received either outpatient (OP) or inpatient (IP) hospi-
talisation treatment for one or more CMDs—HTN, coro-
nary heart disease (CHD: angina, myocardial infarction 
or heart failure), ST, DM or its complications, and CKD in 
the previous 12 months. If affirmative for OP treatment, 
participants were asked the number of visits and medical 
expenditures for each of the following categories: consul-
tation fees, laboratory or radiological tests, medications, 
physical therapy and home nurse care for each visit in the 
past 12 months. If the participant was hospitalised for the 
above- mentioned CMDs, then they were asked about the 
number of times hospitalised, length of hospital stay(s), 
and associated costs of hospital stays, costs of any surgical 
or other procedures, lab tests and medications for each 
hospitalisation in the past 12 months.
Additionally, for each OP visit and/or hospitalisation, 
we collected data on direct non- medical expenditures 
such as expenses on travel to and from clinic/hospital, 
time spent waiting at the clinic, consultation time (for 
OP), and the number of days spent by the respondent 
and their caregivers in the hospital (for IP).
We also collected information on the type of healthcare 
setting—government, private, charity or other. Further, 
participants were asked about the source(s) of financing 
used (own savings, payment by family members, insurance, 
loans (relatives/ friends or banks/other lenders) and sale 
of assets) and the proportion of healthcare expenditures 
that were derived from each of these sources.
Variable definitions
Covariates
We used participants’ reported age, gender, marital status, 
education, employment status and occupation as covari-
ates. Based on participants’ responses, we categorised 
education level (up to primary schooling, high school 
or secondary, college graduation and above); wealth; 
employment status (employed, homemaker, student, 
unemployed, retired) and occupation (not working 
outside the home, unskilled/semiskilled, trained/skilled, 
white- collar). For calculating wealth, we used an index 
of household amenities and assets. We used principal 
components analysis methods14 and categorised wealth 
in tertiles. Details of these methods are provided in a 
previous publication.13
Per-patient expenditures
We used cost- of- illness methods to calculate the economic 
burdens of CMDs. To provide comprehensive estimates of 
health expenditures, we included both direct medical and 
direct non- medical expenditures of each disease annu-
ally.16 We derived direct medical expenditures for each 
CMD by adding the expenditures reported by participants 
for medications, lab investigations, OP consultations and 
hospitalisations. We calculated direct non- medical expen-
ditures by aggregating participant- reported transporta-
tion costs to and from the clinic/hospital and the costs 
of boarding and lodging of attendants (only in the case 
of hospitalisation). We estimated total direct expendi-
tures by adding direct medical and non- medical expendi-
tures.17 Here, we report annual per- patient expenditures 
for individual CMDs—DM, HTN, CHD, ST and CKD—
and combinations of these: (1) DM+HTN and (2) HTN/
DM+HD/CKD/ST (ie, hypertension or diabetes with any 
of heart disease, chronic kidney disease, and/or stroke).
Indirect costs (ie, productivity loss) were estimated on 
the basis of the number of days lost for consultations, 
hospitalisations or treatments17 reported by participants 
of economically productive age (20–64 years).18 We used 
the time spent in the clinic (waiting/consultation or 
for investigations) and the number of days hospitalised 
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for this calculation. We considered less than 4 hours as 
half a day loss and 4 hours or more as loss of an entire 
day (considering an average of 8 working hours a day as 
the standard). Since individual- level income data were 
not available to estimate productivity losses, we used 
minimum wage to compute indirect costs due to illness. 
The number of days lost for each participant was then 
multiplied by the minimum wage for that city in the 
year 2017–2018. Minimum wages used for Chennai, New 
Delhi and Karachi were 352 Indian rupees (Int$23.3),19 
534 Indian rupees (Int$35.3)20 and 500 Pakistani rupees 
(Int$20.5) per day,21 respectively.
The total costs of diseases were calculated by adding 
direct and indirect costs (figure 1). We extrapolated these 
data to estimate the total economic burden for each city. 
We estimated the portion of expenditures that were OOP 
by subtracting the amounts paid by insurance from total 
direct expenditures.22
Distress financing
Participants were considered to be incurring distress 
financing (DF) if the participants reported that their 
source of financing treatment of CMDs included 
borrowing money from relatives or friends, taking loans 
from banks or other lenders, or selling assets.23
We converted all reported direct and indirect expen-
ditures in Indian rupees and Pakistani rupees to 2011 
Purchasing Power Parity- adjusted International Dollars 
(Int$), the year for which data were collected and 
presented in this paper.24 We inflated these costs to the 
2018 US$ value.25 26
Data analysis
Sampling weights were used to account for the complex, 
multistage design of the CARRS surveys to ensure that the 
findings are representative of each city. Demographic and 
socioeconomic profiles were described as percentages 
(with 95% CIs), from each city and cumulatively.
For all medical expenditures, each unit of resource use 
was multiplied with their frequency in the last 1 year, to 
calculate the annual cost for that category. The expendi-
ture on OP and IP treatments were presented as means 
(SE). Given that cost data were unlikely to be normally 
distributed, the bootstrap method was used to calculate 
SEs and 95% CIs were estimated for average costs.27 We 
also estimated individual expenditures across different 
age groups, socioeconomic groups, educational, occupa-
tion groups and cities.
We estimated what proportion of health expenditures 
were financed through different means: OOP expen-
ditures, insurance and others. We then calculated the 
proportion of adults that needed to avail of DF to cover 
health expenditures. Then, we used univariate and 
multivariate logistic regression to assess which social, 
demographic and clinical factors were associated with 
higher probability of DF. The multivariate models were 
constructed using those variables that were significant 
(p<0.1) in the univariate models using a forward stepwise 
approach.
To calculate the economic burden for each city, we calcu-
lated the size of the at- risk population (ie, age ≥20 years) 
from the age- specific distributions of the populations of 
New Delhi, Chennai and Karachi using the latest available 
census data.28 29 For diagnosed CMDs, we estimated preva-
lence in each city using self- reported physician- diagnosed 
DM, HTN, CHD, ST and CKD from the CARRS survey. For 
DM and HTN, we also estimated the total prevalence (both 
diagnosed and undiagnosed) by including participants 
who did not report DM or HTN, but had measured blood 
pressure ≥140/90 mm Hg (for HTN) and measured fasting 
plasma glucose ≥126 mg/dL or glycated haemoglobin 
HbA1c ≥6.5% (for DM). The size of the affected population 
was calculated by multiplying the age- standardised preva-
lence of disease from the CARRS survey with the popula-
tion at risk in each city. Prevalence was standardised to the 
2010 world population, to compare these estimates with 
other global cities that have different population structures. 
Then, the per- patient average annual cost for each disease 
was applied to the size of the affected population, to get 
the total estimated cost of the disease for the city using the 
following equation:
Cost projections for city=size of the affected popu-
lation×nnual per- person expenditures for the disease 
where the size of affected population=age- standardised 
prevalence for the disease (standardised to world popu-
lation 2010)×size of the population aged 20 years and 
above/100.
Figure 1 Annual mean cost per person of cardio- metabolic diseases in three cities in South Asia.
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STATA V.12.1 (STATA Corporation, College Station, 
Texas, USA) was used for statistical analysis.
Patient and public involvement
It was not appropriate or possible to involve patients or 
the public in the design, or conduct, or reporting, or 
dissemination of our research.
Role of the funding source
The funding source had no role in the design of this study 
and will not have any role during its execution, analyses, 
interpretation of the data or decision to submit results.
RESULTS
Out of the 16 287 recruited participants, 3707 had self- 
reported CMDs (HTN, CHD, ST, DM and/or CKD). 
However, only 2883 (78%) had received treatment in 
the prior year. Nearly 14% of patients with CHD, 63% of 
patients with ST and 45% of patients with CKD reported 
not receiving treatment in the last 12 months (see online 
supplemental table S1).
Table 1 presents demographic, socioeconomic and 
CVD risk factor characteristics of the 2883 respondents 
who were treated for CMDs in the prior year. The mean 
age of participants was 51.4 (SD=11.4) years, and women 
Table 1 Demographic and socioeconomic characteristics of participants (who provided cost data) across all cities (total 
N=2883)
Chennai (N=1228) New Delhi (N=1021) Karachi (N=634) Total (N=2883)
% 95% CI % 95% CI % 95% CI % 95% CI
Age (N=2883)
  <45 (n=677) 32.6 (26.1 to 39.7) 25 (18.9 to 32.3) 27.3 (17.2 to 40.3) 28.6 (24.0 to 33.6)
  45–59 (n=1319) 42.9 (36.5 to 49.6) 50.6 (41.9 to 59.4) 44.8 (31.7 to 58.7) 46.2 (40.6 to 52.0)
  >60 (n=887) 24.5(19.7 to 30.1) 24.3 (18.2 to 31.7) 27.9 (18.4 to 39.9) 25.2 (21.2 to 29.7)
  Mean age 50.5 (49.1 to 52.0) 52.3 (50.8 to 53.8) 51.6 (48.9 to 54.3) 51.4 (50.4 to 52.5)
Gender (2883)
  Male (n=1255) 41.3 (35.1 to 47.7) 49.3 (40.5 to 58.1) 36.6 (25.3 to 49.6) 43.2 (37.9 to 48.7)
  Female (n=1628) 58.7 (52.3 to 64.9) 50.7 (41.9 to 59.5) 63.4 (50.4 to 74.7) 56.8 (51.3 to 62.1)
Education (2883)
  Up to primary schooling (n=671) 21.6 (18.4 to 25.2) 14.5 (11.1 to 18.7) 34 (28.9 to 39.6) 21.7 (19.3 to 24.3)
  High school to secondary (n=1727) 71.1 (67.2 to 74.7) 51.5 (47.6 to 55.3) 52.8 (47.6 to 58.0) 59.6 (57.1 to 62.2)
  Graduation and above (n=485) 7.3 (5.5 to 9.6) 34.1 (29.4 to 39.1) 13.1 (9.3 to 18.2) 18.6 (16.0 to 21.6)
Employment status (2883)
  Employed (n=1045) 37.9 (33.6 to 42.4) 45.6 (38.8 to 52.6) 26.6 (19.9 to 34.6) 38.2 (34.4 to 42.2)
  Student (n=32) 1.6 (0.7 to 3.7) 0.5 (0.2 to 1.6) 3 (1.7 to 5.1) 1.5 (0.9 to 2.5)
  Housewife (n=1333) 46.3 (40.9 to 51.9) 42.1 (34.8 to 49.8) 50.7 (41.4 to 59.9) 45.7 (41.2 to 50.3)
  Retired (n=307) 7.3 (5.3 to 9.9) 9.8 (6.9 to 13.6) 10.7 (6.7 to 16.8) 9 (7.2 to 11.1)
  Unemployed (n=166) 7 (4.9 to 9.8) 2 (1.2 to 3.1) 9 (6.5 to 12.3) 5.5 (4.4 to 7.0)
Occupation (2883)
  Not working (n=1838) 62.1 (57.6 to 66.4) 54.4 (47.4 to 61.2) 73.4 (65.4 to 80.1) 61.8 (57.8 to 65.6)
  Semiskilled/unskilled (n=353) 19.2 (16.2 to 22.7) 8.6 (6.2 to 11.9) 9.5 (6.8 to 13.2) 13.1 (11.1 to 15.3)
  Trained/skilled (n=587) 17.7 (14.7 to 21.2) 28.8 (24.2 to 33.9) 14.2 (9.9 to 19.8) 21.1 (18.4 to 24.0)
  White collar (n=105) 1 (0.5 to 1.7) 8.2 (5.7 to 11.6) 2.9 (1.6 to 5.2) 4.1 (3.0 to 5.5)
Wealth index (2883)
  1 (n=637) 35.3 (31.1 to 39.7) 12.7 (9.6 to 16.8) 9.9 (8.1 to 12.1) 21.2 (18.5 to 24.1)
  2 (n=960) 38.6 (34.6 to 42.7) 19.2 (16.0 to 22.8) 41.7 (36.2 to 47.3) 32 (29.4 to 34.7)
  3 (n=1286) 26.1 (22.9 to 29.6) 68.1 (62.3 to 73.3) 48.4 (42.4 to 54.4) 46.8 (43.1 to 50.6)
Marital status (2883)
  Single (n=49) 1.1 (0.6 to 1.9) 1 (0.5 to 1.7) 3 (1.7 to 5.2) 1.5 (1.1 to 2.0)
  Married (n=2517) 91 (88.5 to 93.0) 88.9 (86.3 to 91.1) 83.4 (79.2 to 86.9) 88.5 (86.7 to 90.1)
  Widow/widower (n=303) 7.2 (5.3 to 9.7) 9.9 (7.9 to 12.4) 13.4 (10.0 to 17.8) 9.6 (8.1 to 11.3)
  Separated/divorced (n=14) 0.7 (0.4 to 1.4) 0.2 (0.1 to 1.0) 0.1 (0.0 to 0.9) 0.4 (0.2 to 0.7)
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constituted 56.8%. Most sociodemographic characteris-
tics were distributed similarly among all the cities except 
wealth and education. New Delhi had the larger propor-
tions of participants in the highest wealth tertile (68%) 
and graduate- level education (34%), compared with 
28.6% and 48.4% in Chennai, and 7.3% and 13.1% in 
Karachi, respectively.
For both OP and IP care, more than 60% of partici-
pants reported using private health facilities. Across all 
three cities, the primary source of financing was their 
own household savings (52.5% in OP and 47.3% in IP). 
Overall, insurance covered 3.3% of OP and 14.2% of IP 
services used. Chennai had the lowest insurance coverage 
(OP: 2.1%, IP: 8%) and highest government health facility 
utilisation (OP: 28.1%, IP: 22.2%) among all three cities’ 
residents. The average time spent in OP visits and time to 
each health facility was 60 and 28 min, respectively. The 
average number of OP visits for all CMDs ranged from 
5 to 11 per year, with the lower end of visits observed for 
patients with DM and the higher end of visits observed for 
patients with CKD (table 2).
Table 2 Type of health facility and source of financing for healthcare
Chennai New Delhi Karachi Total
Type of health facility (OP care) (2852)
  Government (n=786) 36.5 (32.7, 40.5) 26.1 (22.3, 30.4) 10.1 (7.9, 13.0) 26.8 (24.4, 29.3)
  Private (n=2021) 62.4 (58.4, 66.3) 72.3 (68.1, 76.2) 87.5 (84.6, 90.0) 71.7 (69.2, 74.0)
  Charity (n=45) 1.1 (0.5, 2.1) 1.5 (0.8, 2.7) 2.3 (1.4, 3.7) 1.5 (1.1, 2.1)
Type of health facility (IP care) (n=114)
  Government (n=40) 48.7 (32.4, 65.4) 33.2 (17.7, 53.4) 27.1 (16.2, 41.8) 37.2 (28.6, 46.8)
  Private (n=71) 48.7 (32.5, 65.2) 66.8 (46.6, 82.3) 67.9 (53.2, 79.8) 60.1 (50.7, 68.9)
  Charity (n=3) 2.6 (0.3, 16.8) 0 5 (1.2, 17.9) 2.6 (0.8, 8.0)
  Time spent in OP per visit (min) (N=2875) (mean 
(SD))
68.6 (56.4) 53.5 (63.7) 51.2 (55.8) 59.1 (59.5)
  Time spent to reach hospital/clinic per visit (min) 
(N=2875) (mean (SD))
29.6 (21.1) 28.9 (26.2) 23.8 (18.8) 28 (23)
  Number of OP visit (N=2875) (mean (SD)) 5.2 (5) 7.1 (9.7) 6.4 (8.1) 6.2 (7.9)
   HTN 5.2 (4.9) 7.2 (10.2) 6.7 (9.4) 6.4 (8.6)
   DM 4.5 (4.3) 5.6 (6.1) 6.5 (8.8) 5.2 (5.9)
   HD 6.5 (6.5) 6.3 (8.5) 3.8 (4.6) 5.6 (7)
   CKD 2.6 (1.3) 54.4* (43.6) 4.8 (6.5) 11 (23.7)
   ST 7.2 (6) 6.9 (6.4) 10.7 (1) 8.1 (5.5)
   HTN+DM 5.6 (5) 7.8 (8) 6.4 (5.7) 6.5 (6.5)
   HTN/DM+HD/CKD/ST 6.5 (5.7) 9.7 (15.3) 6.6 (5.8) 7.6 (10)
OP visit financing source† (N=2876)
  Own saving (N=1511) 44.8 (41.0, 48.6) 61.3 (55.5, 66.8) 51.8 (46.8, 56.7) 52.5 (49.4, 55.6)
  Family members paid (N=1010) 28.1 (24.3, 32.2) 37 (31.5, 42.8) 45.5 (39.7, 51.4) 35.3 (32.4, 38.3)
  Insurance (N=94) 2.1 (1.2, 3.8) 4.5 (3.3, 6.3) 3.2 (2.0, 5.0) 3.3 (2.6, 4.2)
  Other (government/charity hospital/borrowed from 
friend or bank) (N=366)
28.1 (24.7, 31.8) 2.4 (1.5, 4.1) 0.8 (0.3, 1.8) 12.4 (10.7, 14.4)
IP care financing source† (N=95)
  Own saving (N=44) 50.4 (30.9, 69.8) 51.6 (28.8, 73.8) 39.6 (21.5, 61.1) 47.3 (35.0, 59.9)
  Family members paid (N=35) 32.7 (16.8, 53.9) 19.4 (7.4, 41.8) 45.9 (30.9, 61.7) 33.5 (23.8, 44.9)
  Borrowed from friend, relatives or bank (N=4) 1.9 (0.4, 9.1) 9.3 (1.3, 44.0) 4 (0.5, 24.5) 4.5 (1.3, 14.2)
  Insurance (N=13) 8 (2.4, 23.6) 19.8 (7.6, 42.3) 18.2 (8.2, 35.5) 14.2 (7.7, 24.8)
  Other (government/charity hospital) (N=8) 22.2 (9.3, 44.3) 0 3.2 (0.4, 20.2) 10.5 (4.7, 21.7)
  Distress health financing (N=2866) 29.3 (25.5, 33.4) 37.2 (31.7, 43) 46.4 (40.9, 52.1) 36.1 (33.3, 39)
*Higher than other cities as one participant had 96 visits in last 1 year.
†Multiple responses.
CKD, chronic kidney disease; DM, diabetes mellitus; HD, heart disease; HTN, hypertension; IP, inpatient; OP, outpatient; ST, stroke.
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Per-patient expenditure
Total annual mean health expenditures for all CMDs in 
Chennai, New Delhi, Karachi, and the average for all cities 
were Int$467, Int$979, Int$684 and Int$708, respectively. 
The total average annual direct and indirect expenditure 
per person were Int$536 and Int$171, respectively (figure 1). 
Overall, mean annual costs per patient for HTN, DM, CHD, 
ST, CKD, HT+DM, and HT/DM+CHD/ST/CKD were 
Int$358, Int$469, Int$1831, Int$2425, Int$870, Int$713 and 
Int$2342, respectively. In all cities, average total OP expendi-
tures were higher than IP expenditures. Medications consti-
tuted the majority (46%) of direct expenditures (see online 
supplemental table S2).
Total direct and OOP expenditures were highest in the 
age group 45–60 years. People with higher education had 
more total direct and OOP expenditures. However, as a 
percentage of OOP expenses, people in white- collar jobs 
and of higher wealth index had the lowest expenditures 
relative to their wealth/income (table 3).
Distress financing
DF for Chennai, New Delhi and Karachi were reported 
by 29.2%, 37.2% and 46.4%, respectively, of participants 
with CMDs (table 2). After adjustment for sociodemo-
graphic variables, city and insurance, and female gender, 
unemployed individuals and people without insurance 
were more likely to incur DF. Wealth and education were 
not associated with DF (table 4).
Total economic burden (projections at population level)
Total economic burdens of self- reported CMDs were 
Int$0.4 billion, Int$3.4 billion and Int$1.4 billion in 
Table 3 Sociodemographic correlates of direct and out- of- pocket (OOP) health expenditure
Variable
Total direct expenditure 
cost (in Int$), mean (SE)
OOP expenditure (in Int$), 
mean (SE)
OOP/total direct 
expenditure (%)
Age (years)
  <45 (n=677) 370 (31.6) 312 (21.9) 84.4
  45–59 (n=1319) 606 (70.9) 447 (53.8) 73.8
  >60 (n=887) 596 (82.6) 453 (42.2) 76.1
Gender
  Male (n=1252) 610 (75.8) 467 (50.0) 76.6
  Female (n=1628) 480 (45.7) 367 (27.1) 76.5
Education
  Up to primary schooling (n=671) 479 (99.8) 299 (21.0) 62.4
  High school to secondary (n=1727) 501 (40.0) 409 (32.9) 81.7
  Graduation and above (n=485) 716 (117.9) 545 (71.1) 76.1
Employment status
  Employed (n=1045) 516 (62.) 372 (36.8) 72.1
  Student (n=32) 751 (297.4) 419 (139.1) 55.8
  Housewife (n=1333) 462 (38.7) 400 (32.3) 86.8
  Retired (n=307) 937 (199.8) 589 (88.1) 62.9
  Unemployed (n=166) 580 (178.3) 460 (164.2) 79.4
Occupation
  Not working (n=1838) 548 (46.5) 434 (30.7) 548 (46.5)
  Semiskilled/unskilled (n=353) 306 (36.3) 268 (37.2) 306 (36.3)
  Trained/skilled (n=587) 587 (85.1) 421 (52.3) 587 (85.1)
  White collar (n=105) 824 (412.7) 456 (85.) 824 (412.7)
Wealth index
  1 (n=637) 278 (46.4) 227 (32.7) 81.7
  2 (n=960) 402 (34.7) 312 (22.9) 77.7
  3 (n=1286) 744 (71.2) 560 (51.9) 75.2
City
  Chennai (n=1228) 335 (30.4) 292 (24.4) 87.2
  New Delhi (n=1021) 744 (71.4) 564 (57.6) 75.9
  Karachi (n=634) 550 (84.9) 366 (38.8) 66.5
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Chennai, New Delhi and Karachi, respectively. When we 
assumed everyone with a CMD would need treatment 
(both undetected and self- reported), the estimated total 
city- level costs would be Int$0.5 billion, Int$4.1 billion 
and Int$2 billion, respectively for Chennai, New Delhi 
and Karachi (see online supplemental tables S3 and S4).
DISCUSSION
We calculated total costs of illness (direct and indirect) 
and economic burdens of HTN, CHD, ST, DM and its 
complications, and CKD based on participant reports 
from a large survey of three major cities of South Asia. 
Total annual mean economic costs for all CMDs in these 
Table 4 Univariate and multivariate logistic regression for distress financing
Univariate analysis
P value*
Multivariate analysis
P valueOR (95% CI) OR (95% CI)
Age (years) (2883)
  <45 (n=677) Ref Ref
  45–59 (n=1319) 1.1 (0.8–1.5) 0.5 1.1 (0.8–1.4) 0.33
  >60 (n=887) 1.5 (1.1–2.1) 0.006 1.3 (0.9–1.9) 0.21
Gender (2866)
  Male (n=1245) Ref Ref
  Female (n=1621) 8.2 (6.4–10.5) <0.001 4.4 (2.8–7.1) <0.001
  Education (2870)
  Up to primary schooling (n=671) 3.1 (2.2–4.4) <0.001 1.3 (0.8–1.9) 0.14
  High school to secondary (n=1715) 1.7 (1.3–2.4) 0.001 1.2 (0.9–1.7) 0.21
  Graduation and above (n=484) Ref Ref
Employment status (2866)
  Employed (1038) Ref Ref
  Student (32) 10.3 (4.6–23.2) <0.001 8.9 (2.6–30.1) <0.001
  Housewife (1327) 11.9 (8.8–16.2) <0.001 6.6 (2.6–17.0) <0.001
  Retired (302) 3.1 (2.2–4.6) <0.001 5.5 (2.1–14) <0.001
  Unemployed (167) 8.2 (5.1–13.2) <0.001 10.7 (3.7–30.8) <0.001
Occupation among employed (2866)
  Not working (n=1828) 15.3 (6.6–35) <0.001 Omitted because of collinearity
  Semiskilled/unskilled (n=351) 2.1 (0.9–5.2) 0.1 2.1 (0.8–6) 0.10
  Trained/skilled (n=582) 1.4 (0.6–3.4) 0.4 1.5 (0.6–3.6) 0.50
  White collar (n=105) Ref Ref
Wealth index (2866)
  1 (n=631) Ref Not included in the model
  2 (n=955) 1.2 (0.9–1.7) 0.14
  3 (n=1280) 1.1 (0.8–1.6) 0.4
Marital status (2866)
  Single (n=49) Ref Ref
  Married (n=2503) 1.9 (0.9–3.9) 0.08 1.2 (0.8–1.7) 0.38
  Widow/widower (n=300) 4.2 (1.9–9) <0.001 1.8 (0.9–3.8) 0.12
  Separated/divorced (n=14) 5.9 (1.5–23.5) 0.012 1.6 (0.7–3.4) 0.28
City (2866)
  Chennai (n=1217) Ref Ref
  New Delhi (n=1018) 1.4 (1.04–2) <0.001 2.4 (1.0–20.7) <0.001
  Karachi (n=631) 2.1 (1.6–2.8) <0.001 2.2 (1.7–2.7) <0.001
Insurance (2865)
  Yes (100) Ref Ref
  No (2765) 7.2 (3.5–14.9) <0.001 8.1 (3.8–17.1) <0.001
*Χ2 test.
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three metropolitan cities of South Asia was Int$708. The 
total annual costs per patient for individual CMDs and 
combination of comorbid CMDs varied considerably 
from Int$358 (for HTN) to Int$2342 (for patients with 
multiple comorbidities, that is, HTN/DM with at least 
one complication). Comparing this with gross domestic 
product (GDP) per capita30 for India (Int$4635.9) and 
Pakistan (Int$4309.8), our data show that the presence of 
multiple comorbid CMDs can account for up to 40% of 
per capita expenditures.31
We found New Delhi had the highest total cost of treat-
ment among the three cities. This may be because New 
Delhi has a larger population,28 29 a larger percentage of 
participants in highest wealth index (New Delhi: 68%, 
Chennai: 26%, Karachi: 48%), and a large percentage 
of patients being treated in private for- profit settings 
compared with Chennai and Karachi. Of note, our 
approach used participants’ reported expenditures 
and these would be low or even nearly free for publicly 
funded facilities. As a result, average and total costs in 
Chennai were lower likely due to a higher percentage 
of patients using government health facilities compared 
with the other two cities. It is also possible that the costs 
in for- profit facilities vary and are highest in New Delhi 
compared with the other cities.30
Though total expenditure was highest among the 
wealthiest group, the largest burden of OOP expen-
ditures was observed in the least wealthy group. Previ-
ously published reports from India have also reported 
high OOP expenditures in low socioeconomic 
groups.32–34 This can lead to catastrophic payments 
and impoverishment of households.32 35 Given limited 
government financing (<2% of GDP) in both coun-
tries, private health facilities cater for the majority 
of health service use, both OP (71.7%) and IP care 
(60.1%), and household savings tend to be the most 
common financing source (52.5% of OP and 47.3% of 
IP). This heavy reliance on OOP expenditures (nearly 
80%) is not surprising and mirrors findings from other 
studies from India and other World Bank defined 
LMICs.8 35–37 For example, previous work from India,38 
Pakistan39 and other 23LMICs shows that health insur-
ance coverage dismally low for both OP (3.3%) and 
IP care (14.2%). To address low insurance coverage 
and high OOP expenditure, in the 2018–2019 union 
budget, the government of India has announced the 
Ayushman Bharat Programme to try to increase the 
accessibility, availability and affordability of all level 
of health services in India.40 Evaluation of the impact 
of these financing and policy decisions will be helpful 
in guiding the future modification or continuation of 
these programmes.
We found that medication accounts for the highest 
proportion of direct expenditures, followed by investiga-
tions and consultation fees. This is similar to previous find-
ings from India that analysed the National Sample Survey 
Office data.8 This is also true for most other low- income 
countries as found in a previous review from 2013.12 Since 
medications accounted for the highest proportions of 
OOP expenditures, discount pharmacies and prescrip-
tion of generic medicines may be options to reduce finan-
cial burdens on patients. The government of India has 
already initiated ‘Pradhan Mantri Bhartiya Janaushadhi 
Pariyojana’41 and launched discounted pharmacies, that 
is, Jan Ausahadhi Store (JAS)42 to increase the availability 
of generic medicines. A cost analysis of JAS has shown 
that most of the costs of medicines at JAS are lower than 
branded ones.43
Overall, the prevalence of DF was 36.1% in our study. 
A community- based study conducted in India also reports 
40% DF in urban areas for IP care.44 Women, those that 
are unemployed, and those without insurance were more 
likely to experience DF. Wealth was not associated with 
DF. In another study conducted in four LMICs including 
India, DF was 65% for India which is markedly higher 
than our study as that study was focused on recently hospi-
talised patients, though in that study, DF was also more 
common among female and unemployed participants, 
and participants without insurance.23 Insurance appears 
to be a strong predictor of avoiding DF; as such, universal 
health coverage may be an important avenue to poten-
tially decrease the financial risks associated with CMDs. In 
addition, the availability of government health facilities 
may also lower total OOP expenditures, as was observed 
in comparing costs in Chennai and the other cities.
CMDs require regular follow- up visits to health facilities 
leading to loss of working time both for the patient and 
caregivers; these non- medical and indirect costs contrib-
uted to 14% of the total economic cost in our study. Other 
studies from India and Pakistan suggest indirect costs 
for patients with DM and their caregivers were 28.76% 
and 15%, respectively.39 45 Due to differences in methods 
(minimum wage vs actual individual income), our esti-
mates for indirect costs were likely conservative. In addi-
tion to health expenditures, the economies and societies 
in India and Pakistan also suffer from lost productivity due 
to deaths from HD, ST and DM amounting to $53 billion 
and $3.5 billion, respectively over the period 2005–2015.46 
These should also be factored into policy decisions 
regarding action to address CMDs going forward.
Twenty- two per cent of total participants with self- 
reported CMDs did not report receiving any treatment. 
Though they were not enumerated in this study, in the 
absence of treatment, these individuals may experience 
acute complications, which are hugely expensive resulting 
in higher financial burdens and sufferings. Therefore, 
awareness regarding regular treatment in CMDs and 
more effective preventive and screening strategies are 
required to prevent long- term disability.8
The high prevalence and economic cost of CMDs in 
India and Pakistan underline the importance of policy 
and governance to help steer current health system regu-
lations toward more efficient use of healthcare and better 
health outcomes. To address acute and chronic disease 
needs, there is a need to develop a system that provides 
high- quality, accessible and affordable services.47
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Strengths and limitations
To the best of our knowledge, this was the first large 
community- based study from South Asia with primary 
data collected for cost- of- illness estimation for CMDs. 
These data were representative of their respective cities. 
We used age- standardised prevalence, standardised to the 
world’s population in 2010 for calculation of economic 
burdens to cities. Epidemiological (prevalence of CMDs) 
and economic survey (direct medical and non- medical 
cost, indirect cost and source of financing) data were 
collected from the same population which is an ideal 
approach to calculate cost of illness and loss of produc-
tivity for a city.9
Nevertheless, our study had some limitations. The 
health service utilisation and expenditure data were 
self- reported and are likely subject to reporting biases. 
However, for community- level cost data collection, self- 
report is the most common method used. Utilisation 
and cost of treatment were collected for the last 1 year, 
therefore it is subjected to recall bias. That said, it is 
unclear which direction the recall bias would influence 
our estimates—that is, were they higher or lower than in 
reality? We expect that standardised training and proto-
cols and stringent monitoring of surveys would have mini-
mised these biases. For indirect cost calculations, due to 
unavailability of data on attendant costs for OP visits, the 
actual income of the participant, an actual number of 
days lost for OP care and value of premature mortality 
caused by CMDs, we expect tour indirect cost estimates 
are extremely conservative. However, as indirect cost 
contributes less than 15% of total economic costs, we 
would not expect huge variation in total economic costs. 
For the cost estimates for the undiagnosed, we cannot be 
sure of this and would propose that the costs of people 
with undiagnosed DM lie somewhere between 0.5 and 1.5 
times what they are for the diagnosed. Therefore, we took 
the midpoint of 1.0 times (or a 1:1 conversion). Due to 
the unavailability of recent census data from Pakistan, we 
used data from 1998 to calculate the population at risk, 
which can lead to underestimation of total economic 
burdens for Karachi. All calculated costs do not consider 
subsidised health services and data to incorporate this 
component are not available.
CONCLUSIONS
CMDs constitute a huge economic burden in South Asia. 
Our analysis took the users’ perspective on expenditures 
and used a cost- of- illness approach. This study high-
lights the direct, indirect and OOP expenditure CMDs 
in three major cities of India and Pakistan. Importantly, 
80% of direct expenditures were OOP and 36% reported 
requiring DF. These findings highlight major gaps in 
insurance coverage, health financing, and limited avail-
ability and utilisation of public health facilities.
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